Caris Life Sciences has selected Illumina’s MiSeq sequencing system to support Caris’ evidence-based molecular profiling service. The MiSeq system will be deployed to enable simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina’s amplicon-based assay.

Caris Life Sciences’ molecular profiling service offers tumor biomarker analyses coupled with a clinical literature review, which matches potential therapies to patient-specific biomarker information. Using a range of technologies, this service is designed to help oncologists personalize care for cancer patients. According to Caris, the addition of next-generation sequencing to their molecular profiling service represents the next step in the evolution of this offering.

“We are pleased to be the selected sequencing platform for Caris Life Sciences, . . . whose molecular profiling service has been ordered for more than 40,000 patients to date,” said Matt Posard, senior vice president and general manager of Illumina’s Translational and Consumer Genomics business. “This collaboration is an excellent example of applying next-generation sequencing with the goal of improving patient outcomes.”

Illumina’s MiSeq is a fully integrated personal sequencer designed to deliver streamlined performance from sample prep through automated data analysis and storage in the BaseSpace cloud. Caris offers next-generation sequencing commercially in their laboratory, and will replace its current sequencing technology with the MiSeq system.

Previous articlePfizer, Auxilium End Xiapex Collaboration
Next articleDiscoveRx Acquires BioSeek